Neuropsychiatric Symptoms (NPS), particularly psychosis, are common in dementia and can significantly impact patient outcomes, caregivers and disease trajectory. Psychosis, which includes hallucinations and delusions, occurs in up to 50% of people with dementia and has been linked with lower quality of life and faster cognitive decline. While best practice guidelines have highlighted the importance of non-pharmacological treatments for NPS, evidence-based non-pharmacological approaches are limited. This exploratory analysis of a cluster randomized control trial (RCT) from the WHELD programme compares the WHELD/Brief Psychosocial Therapy intervention with treatment as usual in a 9-month trial across 69 UK nursing homes (N=8477, 553 completed). The current report analyzed outcomes for the participants with dementia-related psychosis (N=163) participating in the trial. Whilst the WHELD/Brief Psychosocial Therapy intervention did not significantly reduce NPI psychosis score, it did significantly improve apathy (p=0.006), agitation (p=0.038) and quality of life (p=0.01) in participants with psychosis. In addition there was a non-significant numerical improvement in caregiver perceived disruptiveness. These findings suggest that whilst the WHELD/ Brief Psychosocial Therapy intervention does not directly alleviate psychosis in people with dementia, it does significantly improve related neuropsychiatric symptoms and quality of life, offering meaningful benefits to people with dementia experiencing distressing psychotic symptoms.

The authors have declared no competing interest.

NCT01855152

This research was funded by the National Institute of Health Research, Programme Grant for Applied Research (Ref: RP-PG-0608-10133). https://www.nihr.ac.uk/funding-and-support/funding-for-research-studies/funding-programmes/programme-grants-for-applied-research/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received full ethical approval from the South-Central Oxford Research Ethics Committee

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors